Blum Robert I 4

What Happened
Robert I. Blum, President & CEO and a director of Cytokinetics (CYTK), reported two sales on 2026-03-17 totaling 36,601 shares for aggregate proceeds of about $2,274,752. The filings show: 12,673 shares at $62.15 ($787,627) and 23,928 shares at $62.15 ($1,487,125). Both transactions are described as company-compelled sell-to-cover actions to satisfy tax withholding obligations arising from vested RSUs — not discretionary open-market liquidations.

Key Details

• Transaction dates and prices: 2026-03-17 — 12,673 shares @ $62.15 and 23,928 shares @ $62.15.
• Total proceeds: ~$2.27 million (combined).
• Transaction type: S (Sale); specifically recorded as company-compelled sell-to-cover to cover RSU tax withholding (footnotes F1, F2).
• Ownership after transaction: Not specified in the supplied Form 4 summary.
• Additional notes: Filing dated 2026-03-18 for transactions on 2026-03-17 (filed timely). Footnotes indicate some shares are held by The Bridget Blum 2003 Irrevocable Trust and The Brittany Blum 2003 Irrevocable Trust (F3, F4).

Context
Sell-to-cover transactions are routine when restricted stock units vest and the company or broker sells a portion of the shares to cover tax withholding; they generally do not carry the same signal as voluntary sales for cash. This filing documents tax-related disposals rather than an opportunistic sell by the insider.